Moderna Says Late-Stage Study Readout For Cytomegalovirus Vaccine Candidate May Come As Early As The End Of Next Year
Portfolio Pulse from Benzinga Newsdesk
Moderna has announced that the late-stage study results for its Cytomegalovirus vaccine candidate may be available as early as the end of next year.
September 13, 2023 | 8:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's announcement about the potential early release of late-stage study results for its Cytomegalovirus vaccine candidate could impact its stock positively.
The announcement of potential early release of late-stage study results for a vaccine candidate is generally seen as positive news. This could lead to increased investor confidence in Moderna, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100